Hospitals and philanthropies in the US are forming their own drug company called Civica Rx.
Researchers can apply to receive $100,000 in matched funds from Intermountain to cover project costs related to high-throughput genomic sequencing.
The partnership has allowed Philips to provide a single view of cancer patient's status, including genomic test results, through the FDA-cleared IntelliSite Pathology Solution.
The health system hopes to pair the data with nearly three decades worth of electronic health records as well as medical histories provided by contributors.
Following several Sync for Genes pilots, FHIR Genomics advocates are pushing for adoption of their standard to make omics data compatible with EHRs.
Results from a randomized clinical trial known as GIFT suggest that genotype-guided warfarin dosing is linked to fewer adverse events than clinical dosing.
The company launched the RxMatch Antidepressant Panel as the first step to grow beyond precision oncology and offer genomic assays for a wider range of diseases.
The researchers now plan to apply the linked-read technology to additional cancer samples as well as other disease cohorts with suspected structural variants.
The Intermountain spinout will use the Series A financing to commercialize and expand its precision cancer care offering, including the TheraMap solution.
Philips has teamed with Illumina and Intermountain Healthcare's Navican on informatics for precision medicine and signed a genome analytics deal with Memorial Sloan Kettering Cancer Center.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.